TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Volume of gastric content aspirated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Executive function - attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vision Quality During the Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Daily Wear Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Pseudomonas aeruginosa colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Participants With and Without Diagnosis of an Epilepsy Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 5 scale score of glottic view
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time and number of attempts required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of irritation of the pharynx, epiglottis, and arytenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with new T2 lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Clinician Erythema Assessment and Subject's Self Assessment at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Clinician Erythema Assessment and Subject's Self Assessment at Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: degree of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adult Caregiver Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Coping with Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kaplan-Meier Cumulative Incidence Rate of Major Adverse Cardiovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients With Long Term Non-persistence to P2Y12 Receptor Inhibitor
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Meeting ASAS20 Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: adipocyte fatty acid binding protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of SAR342434
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve (AUC) of SAR342434
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 12 hours post administration (GIR-AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of new biomarkers of ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intervention-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Low birth weight of infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Occurrence of Major Adverse Cardiovascular Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacologic increase in CD31+ (mature endothelial cell)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in subaortic velocity time integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving Target Lipid Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Reduced Cardiovascular Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Meal tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median time to complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left atrial appendage (LAA) patency at 45 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pathologic Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With at Least One Inappropriate MAI Criterion
Endpoint domain: Adverse events/effects
Primary endpoint: measures of stress and mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of SSTI
Endpoint domain: Adverse events/effects
Primary endpoint: Follow up complications after PPCI
Endpoint domain: Adverse events/effects
Primary endpoint: Level 3-5 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: maximal dose tolerated
Endpoint domain: Adverse events/effects
Primary endpoint: AUC and Cmax for desloratadine, 3-OH desloratadine, and fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: optic nerve sheath diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects Who Are Pain Free at the 2-hour Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Are Nausea Free at the 2-hour Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast milk cysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of developing persistent symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Urinary Voids Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk of complications from antibiotic use in acute cystitis
Endpoint domain: Adverse events/effects
Primary endpoint: Spearman correlation coefficient between Menopur® dose and AMH serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Arterial Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biomarker Brain Injury Chronology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CTCs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in orthostatic blood fall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: In-hospital survival
Endpoint domain: Mortality/survival
Primary endpoint: Intra-operative death
Endpoint domain: Mortality/survival
Primary endpoint: Long-term death
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Best-Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Post Concussive Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User Experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommended phase II dose (RP2D) of AZD2014
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: simple walking performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: climbing locomotor task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on monthly assessments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes of tumor dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change from baseline characteristic pain intensity at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline spontaneous pain at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bacteria per each species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Probing pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with laboratory confirmed clinical influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Total radioactivity in plasma and whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity in urine and faeces (excretion balance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of BIBR 953 ZW in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants with clinical cure for VVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of participants with clinical cure for BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of patients receiving a tidal volume higher than 10 ml/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of Dose-limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Lumbar Spine Bone Mineral Density Percent Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Hip Bone Mineral Density Percent Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distal 1/3 Radius Bone Mineral Density Percent Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Provider perception of telehealth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of life with EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CIWA-Ar score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Donor-specific Antibodies Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: functional capillary density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent flow-mediated dilation (FMD) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of Androderm®
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of verticality perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score level of awareness of stroke symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average number of forced mucus expectorations per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dual Task Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Timed Instrumental Activities of Daily Living (TIADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: annual recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in reactive hyperemia index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Y-BOCCS Rating OCD Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glycosylated Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in kg/m^2 (Body Mass Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Delay Discounting Area Under the Curve (Normalized)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of olaparib and irinotecan and/or temozolomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resolution of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number Of Participants Experiencing Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: outcome of neutropenic fever and severe sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Myopia in spherical diopters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of partial pressure of carbon dioxide (pCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Focal Segmental Glomerulosclerosis Permeability Factor (FSPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of intrathecal topotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities and dose-limiting toxicity of intrathecal topotecan
Endpoint domain: Adverse events/effects
Primary endpoint: Topotecan lactone concentrations in the cerebral CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apolipoprotein A-I level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: No reoperations
Endpoint domain: Adverse events/effects
Primary endpoint: Radiological Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature and frequency of serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Nature and frequency of serious adverse device effects (SADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported daily hurt feelings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Curve (AUC) of ABX464 in Sera
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of ABX464 in Sera
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of ABX464 Metabolite (ABX464-N-Glucuronide) in Sera
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Absolute B Cell Cluster Differential 19 Positive (CD19+) Counts in Synovial Tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Absolute B Cell CD19+ Counts in Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: rate of HBsAg loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 specific psychological stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in objectively assessed whole body function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cotinine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clavien-Dindo Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Thromboelastography normal reference values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion on Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Naming correctness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Naming latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pharmacokinetics of ceftobiprole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Myocardial Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of SHR3824
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of SHR3824
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural representation of self
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in local inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of numbers of matured dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with device insertion by hand manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: levels of BMP-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of OPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Infant body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the Pressure Pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematopoiesis efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volume of liquid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Backache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smartphone use level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival without contralateral or unilateral invasive breast cancer at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Survival without invasive breast cancer at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of ANS dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events in subjects treated with botulinum injection
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of CG549
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC) of CG549
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior Rating Inventory of Executive Function for Adults (BRIEF-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Count of Patients With Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Hematologic Response (PR, VGPR, or CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under curve for diagnostic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systemic immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve for distinguishing benign vs malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in provider scores on pre- and post-intervention assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall quality scores in CPV QualityIQ patient simulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in diagnostic and treatment quality scores in CPV QualityIQ patient simulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Aberrant Behavior Checklist-Hyperactivity Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence/nature of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with HRV change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health benefit for patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events collected by spontaneous report
Endpoint domain: Adverse events/effects
Primary endpoint: Change in global functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Allergy follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoarthritis knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes